Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug combinations
Biotech
Arcus halts Gilead-partnered TIGIT trials as it reworks R&D
A key late-stage trial of Arcus Biosciences and Gilead’s anti-TIGIT antibody domvanalimab has flopped.
Ben Adams
Dec 12, 2025 10:00am
Crescent inks $80M Kelun deal, adding ADC to mix with bispecific
Dec 4, 2025 9:50am
Exelixis beats Bayer drug in cancer trial, sending stock higher
Jun 23, 2025 7:30am
Boundless Bio lays off 33% of staff as lead program stumbles
May 27, 2025 8:40am
Immutep's LAG-3 agent posts 'impressive' survival data
May 5, 2025 10:37am
Lilly's oral SERD Ember counts on Verzenio to broaden its glow
Dec 11, 2024 8:15am
